Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the transcript provided. Focus appears to be on internal capacity expansion and organic/inorganic growth through product development and geographical diversification. Recent recruitment of CFO Nilesh Patel aims to strengthen financial management and support growth including mergers and acquisitions, but no direct reference to new fundraising. CAPEX of around ₹22 crores underway for capacity expansion, funded likely through internal accruals or existing resources. Company is positioning for future growth, but no

Any current/future capex/capital investment/strategic investment?

Infinium PharmaChem has ongoing and planned CapEx totaling around ₹22 crore for FY24. ₹15 crore of this has already been incurred towards capacity expansion. The expansion is expected to contribute at least 25% growth to the intermediate segment's top line. A separate ₹11 crore CapEx is planned for a contrast media API unit, expected to be completed by December 2024, contributing 25% to top-line growth from FY25. The capacity expansion is designed for 4-7 years' demand, compliant with US FDA norms for future regulatory approvals. The company is focusing on building strong pharma intermediates

Future growth expectations in sales/revenue/volumes?

The company expects overall top line to reach at least ₹185 crores by FY26, reflecting strong growth. Revenue growth driven by expanding product portfolio (200+ products vs. ~117 four years ago) and new specialty products. Export/domestic revenue mix targeted to balance at 50-50 within next 3 years, up from current 30-70 (export-domestic). Significant growth anticipated in regulated markets like Europe and the US due to REACH registrations and marketing efforts. Contrast Media API raw materials launch expected by FY25 with ₹20-30 crore annual contribution, supporting 25% top-line growth. The i

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets top-line growth of 20-25% annually, driven by capacity expansion and new product launches, particularly contrast media API raw materials contributing significantly from FY26 onwards. EBITDA margins have more than doubled in the last 4 years, currently expected to go beyond 20% in coming years. PAT margins targeted at a sustainable minimum of 10% with specialty products having higher margins than commodity ones. Revenue from new specialty and super-specialty products is increasing, aiming for a 50:50 mix between domestic and export markets within 3 years. Contrast media

Current/ Expected Orderbook/ Pending Orders?

The company has not disclosed any formal pre-bookings or confirmed order book for the expanded capacity. Capacity expansion was driven by market signals and anticipated demand growth over the next 5 to 7 years. There are soft indications and good signals from the market and growing market share, but no formal order confirmation. The company expects substantial growth in demand from both domestic and export markets, including new products and differentiated iodine derivatives. Export markets, particularly Europe and the US, are expected to contribute to increased revenues over the next 2 to 3 y

Infinium Pharmachem LtdQ3 FY24Pharmaceuticals & Biotechnology

Infinium Pharmachem Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹281P/E: 36.0Market Cap: ₹438 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company expects overall top line to reach at least ₹185 crores by FY26, reflecting strong growth.
Revenue growth driven by expanding product portfolio (200+ products vs. ~117 four years ago) and new specialty products.
Export/domestic revenue mix targeted to balance at 50-50 within next 3 years, up from current 30-70 (export-domestic).
Significant growth anticipated in regulated markets like Europe and the US due to REACH registrations and marketing efforts.
Contrast Media API raw materials launch expected by FY25 with ₹20-30 crore annual contribution, supporting 25% top-line growth.
The iodine derivative industry grows at 5-6% CAGR; company targeting increasing market share (from 5% now to 15% by 2030 domestically).
New applications in sectors beyond pharma (cosmetics, nutraceuticals, solar, electronics, paints) projected to contribute around 8% revenue by FY26.
Capacity expansions are planned for the next 5-7 years to meet demand without disruption.

Margin guidance

Category 3

The company targets top-line growth of 20-25% annually, driven by capacity expansion and new product launches, particularly contrast media API raw materials contributing significantly from FY26 onwards.
EBITDA margins have more than doubled in the last 4 years, currently expected to go beyond 20% in coming years.
PAT margins targeted at a sustainable minimum of 10% with specialty products having higher margins than commodity ones.
Revenue from new specialty and super-specialty products is increasing, aiming for a 50:50 mix between domestic and export markets within 3 years.
Contrast media API products expected to generate Rs. 20-30 crore annually from FY26, boosting margins and profits.
Diversifying exports to Europe and US markets with planned REACH registrations and marketing efforts.
Overall optimism on maintaining strong earnings growth and improving operating profitability through efficiency and product mix enhancement.

See what Infinium Pharmachem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned fundraising through debt or equity in the transcript provided.
Focus appears to be on internal capacity expansion and organic/inorganic growth through product development and geographical diversification.
Recent recruitment of CFO Nilesh Patel aims to strengthen financial management and support growth including mergers and acquisitions, but no direct reference to new fundraising.
CAPEX of around ₹22 crores underway for capacity expansion, funded likely through internal accruals or existing resources.
Company is positioning for future growth, but no stated plans for fresh equity or debt raise at present.

Order book

Yes

The company has not disclosed any formal pre-bookings or confirmed order book for the expanded capacity.
Capacity expansion was driven by market signals and anticipated demand growth over the next 5 to 7 years.
There are soft indications and good signals from the market and growing market share, but no formal order confirmation.
The company expects substantial growth in demand from both domestic and export markets, including new products and differentiated iodine derivatives.
Export markets, particularly Europe and the US, are expected to contribute to increased revenues over the next 2 to 3 years.
Product registrations and pipeline developments support a positive outlook, with diversification beyond pharmaceutical industry.
Overall, the capacity expansion is a proactive step to meet expected long-term demand rather than based on an existing confirmed order backlog.

See what Infinium Pharmachem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Infinium PharmaChem has ongoing and planned CapEx totaling around ₹22 crore for FY24.
₹15 crore of this has already been incurred towards capacity expansion.
The expansion is expected to contribute at least 25% growth to the intermediate segment's top line.
A separate ₹11 crore CapEx is planned for a contrast media API unit, expected to be completed by December 2024, contributing 25% to top-line growth from FY25.
The capacity expansion is designed for 4-7 years' demand, compliant with US FDA norms for future regulatory approvals.
The company is focusing on building strong pharma intermediates and specialty chemical capabilities based on iodine chemistry.
Infinium also has a strategic joint venture in China and a JV in the USA for iodine extraction as part of backward integration.
Future expansions will likely emphasize regulated markets, specialty products, and geographical diversification.

Track Infinium Pharmachem Ltd — get its next earnings analysis in your feed

How does Infinium Pharmachem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInfinium Pharmachem Ltd

Rev 2Mar 3

See where Infinium Pharmachem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Infinium Pharmachem Ltd rank in Pharmaceuticals & Biotechnology?

Compare Infinium Pharmachem Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Infinium Pharmachem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →